1.. NAME OF THEMEDICINAL PRODUCTsalbutamol sulfate and ipratropium Powder

2. QUALITATIVE AND QUANTITATIVE COMPOSITIONThe Powder is a combination of ipratropium bromide monohydrate and salbutamol sulphate. Each valve activation delivers 21 mcg of ipratropium bromide monohydrate (corresponds to 20 mcg ipratropium bromide anhydrous) and 120 mcg of salbutamol sulphate per capsule

3. PHARMACEUTICAL FORMPowder ihalation.

4. Therapeutic indicationsTheproduct is indicated as a bronchodilator for thetreatment of bronchospasm associated with chronic obstructive pulmonary disease in patients who require regular treatment with both ipratropium and salbutamol.

6.PACKAGING INFORMATION Sales pack contains 30 Capsules